Vaccination to Alzheimer Disease. Is it a Promising Tool or a Blind Way?
“Unfortunately, the promising vaccines like the AN 1792 were halted during clinical trials because of adverse effects like meningoencephalitis.”
Slow CCL2-dependent translocation of biopersistent particles from muscle to brain
“Intramuscular injection of alum-containing vaccine was associated with the appearance of aluminum deposits in distant organs, such as spleen and brain where they were still detected one year after injection. Both fluorescent materials injected into muscle translocated to draining lymph nodes (DLNs) and thereafter were detected associated with phagocytes in blood and spleen. Particles linearly accumulated in the brain up to the six-month endpoint; they were first found in perivascular CD11b+ cells and then in microglia and other neural cells. DLN ablation dramatically reduced the biodistribution…. This occurs at a very low rate in normal conditions explaining good overall tolerance of alum despite its strong neurotoxic potential. However, continuously escalating doses of this poorly biodegradable adjuvant in the population may become insidiously unsafe, especially in the case of overimmunization or immature/altered blood brain barrier or high constitutive CCL-2 production.”
The potential importance of steroids in the treatment of autistic spectrum disorders and other disorders involving mercury toxicity.
“There are a number of other diseases that may have a chronic mercury toxicity component, such as Alzheimer’s disease, heart disease, obesity, ALS, asthma, and other various forms of autoimmune disorders.”
Prolonged exposure to low levels of aluminum leads to changes associated with brain aging and neurodegeneration
“Epidemiological studies suggest that aluminum may not be as innocuous as was previously thought and that aluminum may actively promote the onset and progression of Alzheimer’s disease.”
The neurotoxicity of environmental aluminum is still an issue
“Aluminum is a strong candidate for consideration as a subtle promoter of events typically associated with brain aging.”
Increased blood mercury levels in patients with Alzheimer’s disease
“These results demonstrate elevated blood levels of mercury in AD, and they suggest that this increase of mercury levels is associated with high CSF levels of A beta, whereas tau levels were unrelated.”